Histological grading of breast cancer on needle core biopsy: The role of immunohistochemical assessment of proliferation

Histopathology

Volumn 57, Issue 2, 2010, Pages 212-219

  Kwok, T'Ng Chang ^a   Rakha, Emad A ^a   Lee, Andrew H S ^a   Grainge, Matthew ^b   Green, Andrew R ^a   Ellis, Ian O ^a   Powe, Desmond G ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

breast neoplasm; histological grading; needle core biopsy

Indexed keywords

EOSIN; HEMATOXYLIN; HISTONE H3; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CELL COUNT; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MITOSIS; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MITOTIC INDEX; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 77955810826     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03620.x     Document Type: Article

References (59)

1. O'Leary R, Hawkins K, Beazley JCS, Lansdown MRJ, Hanby AM. Agreement between preoperative core needle biopsy and postoperative invasive breast cancer histopathology is not dependent on the amount of clinical material obtained. J. Clin. Pathol. 2004 57 193 195.
2. Cahill RA, Walsh D, Landers RJ, Watson RG. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Ann. Surg. Oncol. 2006 13 45 51.
3. Puglisi F, Scalone S, Bazzocchi M et al. Image-guided core breast biopsy: a suitable method for preoperative biological characterization of small (pT1) breast carcinomas. Cancer Lett. 1998 133 223 229.
4. Ogston KN, Miller ID, Payne S et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003 12 320 327.
5. Elston CW, Ellis IO. Pathological prognostic factors in breast-cancer. 1. The value of histological grade in breast-cancer - experience from a large study with long-term follow-up. Histopathology 1991 19 403 410.
6. Usami S, Moriya T, Amari M et al. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn. J. Clin. Oncol. 2007 37 250 255.
7. Burge CN, Chang HR, Apple SK. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 2006 15 167 172.
8. de Andrade VP, Gobbi H. Accuracy of typing and grading invasive mammary carcinomas on core needle biopsy compared with the excisional specimen. Virchows Arch. 2004 445 597 602.
9. Astall EC, Bobrow LG. Assessment of the accuracy of diagnostic and prognostic information provided by core biopsy in breast carcinoma. J. Pathol. 1998 186 6A.
10. DiLoreto C, Puglisi F, Rimondi G et al. Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. Eur. J. Cancer 1996 32A 1693 1700.
11. Harris GC, Denley HE, Pinder SE et al. Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am. J. Surg. Pathol. 2003 27 11 15.
12. Badoual C, Maruani A, Ghorra C, Lebas P, Avigdor S, Michenet P. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies - correlation with subsequent surgical excisions. Breast 2005 14 22 27.
13. Sharifi S, Peterson MK, Baum AK, Raza S, Schnitt SJ. Assessment of pathologic prognostic factors in breast core needle biopsies. Mod. Pathol. 1999 12 941 945. (Pubitemid 29485266)
14. Rakha EA, Ellis IO. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J. Clin. Pathol. 2007 60 1300 1306.
15. van Diest PJ, van der Wall E, Baak JPA. Prognostic value of proliferation in invasive breast cancer: a review. J. Clin. Pathol. 2004 57 675 681.
16. Jones R, Salter J, A'hern R et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res. Treat. 2009 27 27.
17. Burcombe R, Wilson DG, Dowsett M et al. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res. 2006 8 10.
18. Dai H, van't Veer L, Lamb J et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 2005 65 4059 4066.
19. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal-antibody reactive with a human nuclear antigen associated with cell-proliferation. Int. J. Cancer 1983 31 13 20.
20. Meyer JS, Alvarez C, Milikowski C et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod. Pathol. 2005 18 1067 1078.
21. Connor CS, Tawfik OW, Joyce AJ, Davis MK, Mayo MS, Jewell WR. A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am. J. Surg. 2002 184 322 324.
22. Skaland I, van Diest PJ, Janssen EAM, Gudlaugsson E, Baak JPA. Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years. Hum. Pathol. 2008 39 584 590.
23. Hendzel MJ, Wei Y, Mancini MA et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997 106 348 360.
24. Juan G, Traganos F, James WM et al. Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G(2) and mitosis. Cytometry 1998 32 71 77.
25. Bossard C, Jarry A, Colombeix C et al. Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer assisted determination of mitotic index. J. Clin. Pathol. 2006 59 706 710.
26. Skaland I, Janssen EAM, Gudlaugsson E et al. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod. Pathol. 2007 20 1307 1315.
27. Skaland I, Janssen EAM, Gudlaugsson E et al. Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res. Treat. 2009 114 39 45.
28. Programme NBS, Royal College of Pathologists. Pathology reporting in breast disease, 3rd edn. Publication No. 58.
29. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004 203 661 671.
30. Rakha EA, Putti TC, El-Rehim DMA et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 2006 208 495 506.
31. Aleskandarany M, Green A, Rakha E et al. Growth fraction as a predictor of response to chemotherapy in node negative breast cancer. Int. J. Cancer 2010 126 1761 1769.
32. Elsheikh S, Mohammed R, Aleskandarany M, Rakha E, Green A, Ellis I. Phosphorylated Histone 3 Mitotic Index (PMI); a step towards a more objective grading system in breast carcinoma. J. Pathol. 2009 219 (S1 S21.
33. Bland JM, Altman DG. Statistical-methods for assessing agreement between 2 methods of clinical measurement. Lancet 1986 1 307 310.
34. Delong ER, Delong DM, Clarkepearson DI. Comparing the areas under 2 or more correlated receiver operating characteristic curves - a nonparametric approach. Biometrics 1988 44 837 845.
35. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006 8 216.
36. Darzynkiewicz Z. There's more than one way to skin a cat: yet another way to assess mitotic index by cytometry. Cytometry A 2008 73A 386 387.
37. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008 17 323 334.
38. Iqbal S, Anderson TJ, Marson LP, Prescott RJ, Dixon JM, Miller WR. MIB-1 assessments in breast cancers. Breast 2002 11 252 256.
39. Monticciolo DL. Histologic grading at breast core needle biopsy: comparison with results from the excised breast specimen. Breast J. 2005 11 9 14.
40. Denley H, Pinder SE, Elston CW, Lee AHS, Ellis IO. Preoperative assessment of prognostic factors in breast cancer. J. Clin. Pathol. 2001 54 20 24.
41. McIlhenny C, Doughty JC, George WD, Mallon EA. Optimum number of core biopsies for accurate assessment of histological grade in breast cancer. Br. J. Surg. 2002 89 84 85.
42. Walker RA. Immunohistochemical markers as predictive tools for breast cancer. J. Clin. Pathol. 2008 61 689 696.
43. Hoda SA, Harigopal M. Reporting needle core biopsies of breast carcinomas. Histopathology 2003 43 84 87.
44. Bullough WS. Mitotic activity in the tissues of dead mice, and in tissues kept in physiological salt solutions. Exp. Cell Res. 1950 1 410 420.
45. Edwards JL, Donalson JT. Time of fixation + mitotic index. Am. J. Clin. Pathol. 1964 41 158 162.
46. Graem N, Helweglarsen K. Mitotic-activity and delay in fixation of tumor-tissue - influence of delay in fixation on mitotic-activity of a human osteogenic-sarcoma grown in athymic nude-mice. Acta Pathol. Microbiol. Scand. A 1979 87A 375 378.
47. Cross SS, Start RD, Smith JHF. Does delay in fixation affect the number of mitotic figures in processed tissue. J. Clin. Pathol. 1990 43 597 599.
48. Start RD, Flynn MS, Cross SS, Rogers K, Smith JHF. Is the grading of breast carcinomas affected by a delay in fixation. Virchows Archiv. A Pathol. Anat. Histopathol. 1991 419 475 477.
49. Hodi Z, Chakrabarti J, Lee AHS et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J. Clin. Pathol. 2007 60 299 302.
50. Suthipintawong C, Leong ASY, Chan KW, Vinyuvat S. Immunostaining of estrogen receptor, progesterone receptor, MIB1 antigen, and c-erbB-2 oncoprotein in cytologic specimens: a simplified method with formalin fixation. Diagn. Cytopathol. 1997 17 127 133.
51. Connor AJM, Pinder SE, Elston CW et al. Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated with MIB1 antibody. Breast 1997 6 171 176.
52. Spyratos F, Ferrero-Pous M, Trassard M et al. Correlation between MIB-1 and other proliferation markers - clinical implications of the MIB-1 cutoff value. Cancer 2002 94 2151 2159.
53. Trihia H, Murray S, Price K et al. Ki-67 expression in breast carcinoma - its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker? Cancer 2003 97 1321 1331.
54. Offersen BV, Sorensen FB, Knoop A, Overgaard J, The Danish Breast Cancer Cooperative. The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 2003 43 573 582.
55. Caly M, Genin P, Al Ghuzlan A et al. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases. Anticancer Res. 2004 24 3283 3288.
56. Neri A, Marrelli D, Pedrazzani C et al. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer. Eur. J. Surg. Oncol. 2008 34 1299 1303.
57. vanDiest PJ, vanDam P, HenzenLogmans SC et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. J. Clin. Pathol. 1997 50 801 804.
58. Molino A, Micciolo R, Turazza M et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int. J. Cancer 1997 74 433 437.
59. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. 2005 23 7212 7220.